10X Genomics

TXG56

$14.31arrow_drop_up7.59%$1.01

TXG56

$14.31

arrow_drop_up7.59%$1.01

Performance History

Key Stats
Open	$13.17
Prev. Close	$13.29
EPS	-1.52
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	13.01	14.55
52 Week Range	12.96	57.90

Ratios







EPS	-1.52

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About 10X Genomics (TXG)

10X Genomics Inc (TXG) is a biotechnology company based in Pleasanton, California. The company focuses on developing and marketing innovative solutions for single-cell genomics, allowing researchers to study the genetic makeup of individual cells. With its proprietary technology, 10X Genomics aims to accelerate discoveries in areas such as cancer research, immunology, and neuroscience.

The history of TXG stock price shows a steady growth since the company's initial public offering (IPO) in 2019. The stock has shown resilience even during market downturns, reflecting investors' confidence in 10X Genomics' long-term potential. As of the most recent quote, TXG stock is trading at a significant premium compared to its IPO price, highlighting the positive sentiment surrounding the company.

Websitecall_made

Sector: Healthcare
Industry: Health Information Services
CEO: Dr. Serge Saxonov Ph.D.
Headquarters: Pleasanton
Employees: 1243
Exchange: NASDAQ

Keep an eye on 10X Genomics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is 10X Genomics 's (TXG) price per share?

The current price per share for 10X Genomics (TXG) is $14.31. The stock has seen a price change of $1.01 recently, indicating a 7.6% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for 10X Genomics (TXG)?

For 10X Genomics (TXG), the 52-week high is $57.9, which is 304.61% from the current price. The 52-week low is $12.96, the current price is 10.42% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is 10X Genomics (TXG) a growth stock?

10X Genomics (TXG) has shown an average price growth of -3.66% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying 10X Genomics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is 10X Genomics (TXG) stock price performance year to date (YTD)?

As of the latest data, 10X Genomics (TXG) has a year-to-date price change of -73.65%. Over the past month, the stock has experienced a price change of -7.5%. Over the last three months, the change has been -37.24%. Over the past six months, the figure is -36.65%. Looking at a longer horizon, the five-year price change stands at -78.32%.

help

Is 10X Genomics (TXG) a profitable company?

10X Genomics (TXG) has a net income of -$255.1M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 66.15% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -27.36% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $618.73M, with a revenue growth rate of 19.81%, providing insight into the company's sales performance and growth. The gross profit is $409.31M. Operating income is noted at -$265.33M. Furthermore, the EBITDA is -$134.77M.

help

What is the market capitalization of 10X Genomics (TXG)?

10X Genomics (TXG) has a market capitalization of $1.73B. The average daily trading volume is 14.12, indicating the stock's liquidity and investor engagement.